OMEROS CORP Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
OMEROS CORP (OMER) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 276.50 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-12
- OMEROS CORP share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 160.00K shares, a 95.10% decline year-over-year.
- OMEROS CORP share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 116.50K shares, a 237.68% increase year-over-year.
- OMEROS CORP share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 10.00K shares, a 80.31% decline year-over-year.
- OMEROS CORP share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 16.70K shares, a 91.96% decline year-over-year.
- OMEROS CORP share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 3.32M shares, a 0.24% decline from fiscal 2024.
- OMEROS CORP share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 3.33M shares, a 5.65% increase from fiscal 2023.
- OMEROS CORP share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 3.15M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 160.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | 276.50K shares 10-Q · filed 2026-08-12 | 286.50K shares derived: sum of 3 quarters · filed 2026-08-12 | 303.20K shares derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | 116.50K shares 10-Q · filed 2026-05-13 | 126.50K shares derived: sum of 2 quarters · filed 2026-05-13 | 143.20K shares derived: sum of 3 quarters · filed 2026-05-13 | 3.41M shares derived: sum of 4 quarters · filed 2026-05-13 | |
| 2025-12-31 | 10.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | 26.70K shares derived: sum of 2 quarters · filed 2026-03-31 | 3.29M shares derived: sum of 3 quarters · filed 2026-03-31 | 3.32M shares 10-K · filed 2026-03-31 | |
| 2025-09-30 | 16.70K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | 3.28M shares derived: sum of 2 quarters · filed 2025-11-13 | 3.31M shares 10-Q · filed 2025-11-13 | 3.36M shares derived: sum of 4 quarters · filed 2025-11-13 | |
| 2025-06-30 | 3.26M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | 3.30M shares 10-Q · filed 2025-08-14 | 3.35M shares derived: sum of 3 quarters · filed 2025-08-14 | 3.56M shares derived: sum of 4 quarters · filed 2025-08-14 | |
| 2025-03-31 | 34.50K shares 10-Q · filed 2025-05-15 | 85.30K shares derived: sum of 2 quarters · filed 2025-05-15 | 292.90K shares derived: sum of 3 quarters · filed 2025-05-15 | 3.34M shares derived: sum of 4 quarters · filed 2025-05-15 | |
| 2024-12-31 | 50.80K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | 258.40K shares derived: sum of 2 quarters · filed 2025-03-31 | 3.30M shares derived: sum of 3 quarters · filed 2025-03-31 | 3.33M shares 10-K · filed 2025-03-31 | |
| 2024-09-30 | 207.60K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 3.25M shares derived: sum of 2 quarters · filed 2024-11-13 | 3.28M shares 10-Q · filed 2024-11-13 | ||
| 2024-06-30 | 3.04M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | 3.07M shares 10-Q · filed 2024-08-07 | |||
| 2024-03-31 | 29.80K shares 10-Q · filed 2024-05-15 | ||||
| 2023-12-31 | 3.15M shares 10-K · filed 2024-04-01 | ||||
| 2021-07-31 | 2.10M shares 10-Q · filed 2021-08-09 | ||||
| 2020-09-30 | 39.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | 329.88K shares derived: sum of 2 quarters · filed 2020-11-09 | 2.07M shares 10-Q · filed 2020-11-09 | ||
| 2020-06-30 | 290.38K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | 2.03M shares 10-Q · filed 2020-08-10 | |||
| 2020-03-31 | 1.74M shares 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |